Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm, prospective study on the efficacy and safety of
Bortezomib in addition to standard therapy in patients with refractory rheumatoid arthritis.